Alliance Global Partners Initiates Coverage on GeoVax Labs (NASDAQ:GOVX)

Alliance Global Partners assumed coverage on shares of GeoVax Labs (NASDAQ:GOVX) in a research note released on Monday, Marketbeat.com reports. The firm issued a buy rating and a $15.00 price objective on the stock.

Several other analysts have also weighed in on GOVX. Roth Mkm initiated coverage on GeoVax Labs in a report on Tuesday, July 16th. They set a “buy” rating and a $20.00 price target on the stock. Roth Capital raised shares of GeoVax Labs to a “strong-buy” rating in a research report on Tuesday, July 16th. Noble Financial increased their price objective on shares of GeoVax Labs from $6.00 to $10.00 and gave the company an “outperform” rating in a research report on Monday, August 19th. HC Wainwright reaffirmed a “buy” rating and set a $8.00 target price on shares of GeoVax Labs in a report on Monday, August 12th. Finally, EF Hutton Acquisition Co. I upgraded GeoVax Labs to a “strong-buy” rating in a research report on Tuesday, July 23rd. Four research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, GeoVax Labs has an average rating of “Buy” and a consensus price target of $13.25.

GeoVax Labs Stock Down 3.3 %

GeoVax Labs stock opened at $2.61 on Monday. The stock’s 50 day simple moving average is $2.42 and its two-hundred day simple moving average is $2.59. GeoVax Labs has a fifty-two week low of $1.09 and a fifty-two week high of $11.18.

GeoVax Labs (NASDAQ:GOVX) last announced its earnings results on Tuesday, November 12th. The company reported ($0.91) EPS for the quarter, topping analysts’ consensus estimates of ($1.29) by $0.38. The company had revenue of $2.79 million during the quarter, compared to the consensus estimate of $1.84 million. During the same period in the prior year, the business posted ($4.80) earnings per share. Sell-side analysts forecast that GeoVax Labs will post -5.1 earnings per share for the current year.

GeoVax Labs Company Profile

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.